MEDIA RELEASE PR35753
Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory
Indication to Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
WELLESLEY HILLS, Mass., Aug. 19 /PRNewswire-AsiaNet/ --
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-08066 Therapeutics Program in Phase 2 for
respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.
The PRX-08066 is a Therapeutics Program in Phase 2 for respiratory indication. It is a small molecule, oral
5HT2b antagonist for potential treatment of pulmonary hypertension (PH) associated with chronic obstructive
pulmonary disease (COPD). There is significant reduction in SPAP in conditioned athletes (hypoxia challenge) and
in subjects with PH/COPD. There is potential indication for pulmonary arterial hypertension (PAH) including in
diastolic dysfunction.
The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's
Office - jffinnjr@earthlink.net or +1-781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public
Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for
distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors
and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases
for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include
Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at +1-781-237-8840 or jffinnjr@earthlink.net
SOURCE: Joseph F. Finn, Jr., C.P.A.
CONTACT: Joseph F. Finn, Jr.,
C.P.A.,
+1-781-237-8840,
jffinnjr@earthlink.net
NEWS 
